


PHARMACEUTICAL 2020



SUPERNUS PHARMACEUTICALS INC.



Rank 34 of 362





PHARMACEUTICAL 2020



SUPERNUS PHARMACEUTICALS INC.



Rank 34 of 362

The relative strengths and weaknesses of SUPERNUS PHARMACEUTICALS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of SUPERNUS PHARMACEUTICALS INC. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 262% points. The greatest weakness of SUPERNUS PHARMACEUTICALS INC. is the variable Other Liabilities, reducing the Economic Capital Ratio by 69% points.

The company's Economic Capital Ratio, given in the ranking table, is 132%, being 435% points above the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	472,644
Cost of Goods Sold	16,660
Intangible Assets	24,840
Liabilities, Current	160,587
Liabilities, Non-Current	39,849
Other Assets	645,730
Other Compr. Net Income	10,575
Other Expenses	34,431
Other Liabilities	364,418
Other Net Income	-1,084
Property and Equipment	17,068
Research and Development	69,099
Revenues	392,755
Selling, General and Administrative Expense	158,425

Output Variable	Value in 1000 USD
Assets	1,160,282
Liabilities	564,854
Expenses	278,615
Stockholders Equity	595,428
Net Income	113,056
Comprehensive Net Income	118,344
Economic Capital Ratio	132%